8 min read
Monthly FDA Guidance and Regulatory News Review - August 2026
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...
As you look to transition your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or you are looking to recruit patients quickly to get your early phase trials running, or just need medical writing or biostatistical support for your programs – Veristat can help.
We provide impactful solutions on both a full-service or functional service basis, including strategic regulatory guidance, clinical program design, and IND/CTA support through to successful regulatory approval.
Veristat team member Philip Ho , Business Development Director, Asia Pacific, will be at the venue— ready to listen to your needs and share Veristat’s expertise
Schedule a meeting by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to successful outcomes.

Website: Bio Asia Taiwan
8 min read
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...
8 min read
Aug 14, 2026 Veristat Blog
This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...